DLBCL ESMO EXAM QUESTIONS AND
ANSWERS ALL CORRECT
What is recommended for patients with high-intermediate-risk and high-risk IPI in
DLBCL? - Answer- CNS prophylaxis
What should HIV-positive DLBCL patients receive in addition to antiviral therapy? -
Answer- Same treatment as HIV-negative patients
What is the recommended standard for post-treatment assessment in DLBCL? -
Answer- FDG-PET/CT
What percentage of DLBCL cases ultimately relapse? - Answer- More than 30%
What is a common salvage regimen for relapsed DLBCL? - Answer- R-DHAP or R-ICE
What type of transplantation may be considered for patients with refractory disease,
early relapse, or relapse after ASCT? - Answer- Allogeneic transplantation
What is the molecular subtype of DLBCL associated with a worse prognosis when
treated with R-CHOP? - Answer- Activated B-cell (ABC) subtype
Which kinase inhibitor has shown selective activity in ABC-DLBCL? - Answer- Ibrutinib
What is the standard treatment for DLBCL in patients aged 60-80 years? - Answer- Six
to eight cycles of R-CHOP21
What is the main therapeutic concern for patients with cardiac dysfunction or who are
frail or unfit? - Answer- Substitution or omission of doxorubicin
What is the predictive value of early PET evaluation in DLBCL treatment? - Answer-
Predictive of outcome, reserved for clinical trials
What type of assessment is crucial in guiding treatment choices for elderly DLBCL
patients? - Answer- Comprehensive geriatric assessment
What condition increases the risk of CNS relapse in DLBCL patients? - Answer- MYC
gene rearrangement
What is a common first-line treatment approach for relapsed DLBCL? - Answer-
Salvage chemotherapy followed by ASCT
, What type of molecular defect might be useful in future DLBCL treatment? - Answer-
Frequent and recurrent mutations identified by whole-genome sequencing
What is the role of interim PET in DLBCL treatment? - Answer- Evaluating patients who
might benefit from consolidative ASCT or radiotherapy
What are common symptoms of DLBCL at presentation? - Answer- Enlarging mass,
systemic "B" symptoms (fever, weight loss, night sweats), bone marrow involvement,
extranodal disease
What is the importance of the cell of origin phenotype in DLBCL? - Answer- It is a major
prognostic factor, with germinal center phenotype associated with better outcomes than
activated B-cell phenotype
What are the typical features of the ABC subtype of DLBCL? - Answer- Constitutive
activation of the NF-κB pathway
What is the typical treatment strategy for patients with DLBCL who relapse after ASCT?
- Answer- Allogeneic transplantation or clinical trials with novel drugs
What should be included in the follow-up of patients in second response to DLBCL
treatment? - Answer- Similar follow-up as for first response, including regular physical
examinations and imaging studies
What is a common salvage regimen for DLBCL patients not suitable for high-dose
therapy? - Answer- R-GEMOX (rituximab, gemcitabine, oxaliplatin)
What is the effect of MYC and BCL2 expression in DLBCL? - Answer- Associated with
poor outcome
Which DLBCL treatment requires a comprehensive geriatric assessment? - Answer-
Treatment in elderly poor-prognosis patients
What should be monitored in patients with DLBCL for long-term side-effects of
chemotherapy? - Answer- Development of secondary tumors
What is the main risk of fine-needle aspirate in diagnosing DLBCL? - Answer- It should
not be used as the sole basis for diagnosis
What percentage of non-Hodgkin lymphoma series does DLBCL constitute? - Answer-
30%-58%
What is the crude incidence of DLBCL in Europe? - Answer- 3.8/100,000/year
ANSWERS ALL CORRECT
What is recommended for patients with high-intermediate-risk and high-risk IPI in
DLBCL? - Answer- CNS prophylaxis
What should HIV-positive DLBCL patients receive in addition to antiviral therapy? -
Answer- Same treatment as HIV-negative patients
What is the recommended standard for post-treatment assessment in DLBCL? -
Answer- FDG-PET/CT
What percentage of DLBCL cases ultimately relapse? - Answer- More than 30%
What is a common salvage regimen for relapsed DLBCL? - Answer- R-DHAP or R-ICE
What type of transplantation may be considered for patients with refractory disease,
early relapse, or relapse after ASCT? - Answer- Allogeneic transplantation
What is the molecular subtype of DLBCL associated with a worse prognosis when
treated with R-CHOP? - Answer- Activated B-cell (ABC) subtype
Which kinase inhibitor has shown selective activity in ABC-DLBCL? - Answer- Ibrutinib
What is the standard treatment for DLBCL in patients aged 60-80 years? - Answer- Six
to eight cycles of R-CHOP21
What is the main therapeutic concern for patients with cardiac dysfunction or who are
frail or unfit? - Answer- Substitution or omission of doxorubicin
What is the predictive value of early PET evaluation in DLBCL treatment? - Answer-
Predictive of outcome, reserved for clinical trials
What type of assessment is crucial in guiding treatment choices for elderly DLBCL
patients? - Answer- Comprehensive geriatric assessment
What condition increases the risk of CNS relapse in DLBCL patients? - Answer- MYC
gene rearrangement
What is a common first-line treatment approach for relapsed DLBCL? - Answer-
Salvage chemotherapy followed by ASCT
, What type of molecular defect might be useful in future DLBCL treatment? - Answer-
Frequent and recurrent mutations identified by whole-genome sequencing
What is the role of interim PET in DLBCL treatment? - Answer- Evaluating patients who
might benefit from consolidative ASCT or radiotherapy
What are common symptoms of DLBCL at presentation? - Answer- Enlarging mass,
systemic "B" symptoms (fever, weight loss, night sweats), bone marrow involvement,
extranodal disease
What is the importance of the cell of origin phenotype in DLBCL? - Answer- It is a major
prognostic factor, with germinal center phenotype associated with better outcomes than
activated B-cell phenotype
What are the typical features of the ABC subtype of DLBCL? - Answer- Constitutive
activation of the NF-κB pathway
What is the typical treatment strategy for patients with DLBCL who relapse after ASCT?
- Answer- Allogeneic transplantation or clinical trials with novel drugs
What should be included in the follow-up of patients in second response to DLBCL
treatment? - Answer- Similar follow-up as for first response, including regular physical
examinations and imaging studies
What is a common salvage regimen for DLBCL patients not suitable for high-dose
therapy? - Answer- R-GEMOX (rituximab, gemcitabine, oxaliplatin)
What is the effect of MYC and BCL2 expression in DLBCL? - Answer- Associated with
poor outcome
Which DLBCL treatment requires a comprehensive geriatric assessment? - Answer-
Treatment in elderly poor-prognosis patients
What should be monitored in patients with DLBCL for long-term side-effects of
chemotherapy? - Answer- Development of secondary tumors
What is the main risk of fine-needle aspirate in diagnosing DLBCL? - Answer- It should
not be used as the sole basis for diagnosis
What percentage of non-Hodgkin lymphoma series does DLBCL constitute? - Answer-
30%-58%
What is the crude incidence of DLBCL in Europe? - Answer- 3.8/100,000/year
